Literature DB >> 23902593

Radiofrequency catheter ablation for dyssynchrony-induced dilated cardiomyopathy in an infant.

Elena N Kwon1, Kerri A Carter, Ronald J Kanter.   

Abstract

The relationship between accessory pathway-mediated ventricular preexcitation and left ventricular dyssynchrony-induced dysfunction has been described in patients with Wolff-Parkinson-White (WPW) syndrome in the absence of sustained supraventricular tachycardia (SVT). Supraventricular tachycardia in infants is usually successfully suppressed with antiarrhythmic medications, but catheter ablation has ultimately been required as definitive treatment in medically resistant cases. Catheter ablation has not been described in young infants for dyssynchrony-related dilated cardiomyopathy in the absence of SVT. We describe a case of an infant with WPW who did not have sustained supraventricular tachycardia, but who developed rapid progression of ventricular dysfunction after birth. Preexcitation could not be medically suppressed but was successfully ablated. This was followed by complete resolution of ventricular dysfunction within 2 months.
© 2013 Wiley Periodicals, Inc.

Entities:  

Keywords:  Ablation; Dilated Cardiomyopathy; Pediatrics; Ventricular Dyssynchrony; Wolff-Parkinson-White Syndrome

Mesh:

Year:  2013        PMID: 23902593     DOI: 10.1111/chd.12124

Source DB:  PubMed          Journal:  Congenit Heart Dis        ISSN: 1747-079X            Impact factor:   2.007


  2 in total

1.  The Effect of Accessory Pathway Location on Cardiac Function in Adult Patients with Wolff-Parkinson-White Syndrome.

Authors:  Ying Zhang; Mei Xin; Tongbao Liu; Shangming Song; Wenxin Wang; Jun Li; Bo Xu; Xiaoyang Hou; Bo Dong
Journal:  Cardiol Res Pract       Date:  2021-01-05       Impact factor: 1.866

2.  Successful right anteroseptal manifest accessory pathway cryoablation in a six-month infant with dyssynchrony-induced dilated cardiomyopathy.

Authors:  Pelin Köşger; Fatma Sevinç Şengül; Hasan Candaş Kafalı; Birsen Uçar; Yakup Ergül
Journal:  Anatol J Cardiol       Date:  2019-11       Impact factor: 1.596

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.